Northern,WI  1/28/2013 (BasicsMedia) –  These stocks are moving in the wrong direction early in the week. As we head into the afternoon we now take a look at the some of the losers of the early week.

Missing the analyst estimates always seems to cause a problem as our first downward mover can attest to. VMware Inc. (VMW) is the biggest maker of software that enables computers to run multiple operating systems has fallen on the toughest times since 2008. The company is down some 20% in the morning session. This downward trend is coming after forecasting sales that were less than estimates amid cutbacks from corporate customers.

The stock fell as much as 22 percent to $76.33 after the company said first-quarter revenue will be $1.17 billion to $1.19 billion, in a statement yesterday. Analysts anticipated $1.25 billion, the average of projections compiled by Bloomberg. EMC Corp. (EMC), which owns a majority of VMware, also slumped.

VMware said it’s facing a tougher first half because of a weak economy and sluggish federal government demand, which had an impact on bookings, a measure of future sales. An expected increase in contract renewals won’t occur until later in the year, the Palo Alto, California-based company said

The technology sector seems to be lagging behind the others today as our second downward mover of the day is Seagate Technology Public Limited Company (STX) which is off almost 9% this morning.

Seagate Technology Public Limited Company designs, manufactures, markets, and sells hard disk drives for enterprise storage, client compute, and client non-compute market applications worldwide. The companys products are used in enterprise servers, mainframes, and workstations; desktop and notebook computers; and digital video recorders, gaming consoles, personal data backup systems, portable external storage systems, and digital media systems. It also provides data storage services, including online backup, data protection, and recovery solutions for small and medium-sized businesses.

Are you seeing a theme here in todays article? Bad news does not equal results as Anacor Pharmaceuticals‘ (ANAC.O) is down over 20% trading over 8 times its daily average. Anacor is developing an experimental drug for treating fungal infection of the nails and hopes to show it can cure the disease, but the results fell short of those from a competing drug from Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N).

Anacor said on Tuesday that 6.5 percent patients treated with its drug tavaborole experienced a complete cure, compared with 0.5 percent of patients on a placebo.

Data released by Valeant in November showed that its drug efinaconazole completely cured 17.8 percent of patients, compared with 3.3 percent of those receiving a placebo.

“The degree of benefit fell short of our expectations, and is below that which was recently achieved by Valeant’s efinaconazole,” Cowen and Co analyst Eric Schmidt wrote in a note.

“While we view tavaborole as an FDA approvable therapeutic, investors are likely to question its commercial potential. The Palo Alto, California-based Anacor, which has a market value of about $184 million and has seven drugs in its pipeline. Tavaborole is its most advanced clinical candidate.

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.